ORICELL THERAPEUTICS Trademark
Trademark Overview
On Tuesday, April 2, 2024, a trademark application was filed for ORICELL THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the ORICELL THERAPEUTICS trademark a serial number of 98479754. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Tuesday, October 15, 2024. This trademark is owned by ORICELL THERAPEUTICS INC.. The ORICELL THERAPEUTICS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:
scientific and technological services, namely, scientific research, analysis, and testing in the field of biotechnology and scientific research and design relating thereto; biological research; scientific research in the nature of conducting clinical trials for others; medical research; research and development of new products for others; scientific research; technological research in the field of biotechnology; cell separation technology research services; scientific services relating to the isolation and cultivation of human tissues and cells for scientific and research purposes; scientific research for medical purposes in the area of cancerous diseases; stem cell research services; antibody research and development; pharmaceutical research and development
General Information
| Serial Number | 98479754 |
| Word Mark | ORICELL THERAPEUTICS |
| Filing Date | Tuesday, April 2, 2024 |
| Status | 641 - NON-FINAL ACTION - MAILED |
| Status Date | Tuesday, October 15, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Description of Mark | The mark consists of the literal element ORICELL in a line above the literal element THERAPEUTICS with the O of ORICELL including an inscribed semicircle with a wedge having a dot outside the circle of the O, and the E including horizontal lines, one of which intersects the C. |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| Goods and Services | scientific and technological services, namely, scientific research, analysis, and testing in the field of biotechnology and scientific research and design relating thereto; biological research; scientific research in the nature of conducting clinical trials for others; medical research; research and development of new products for others; scientific research; technological research in the field of biotechnology; cell separation technology research services; scientific services relating to the isolation and cultivation of human tissues and cells for scientific and research purposes; scientific research for medical purposes in the area of cancerous diseases; stem cell research services; antibody research and development; pharmaceutical research and development |
Classification Information
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, April 2, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | ORICELL THERAPEUTICS INC. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Roseland, NJ 07068 |
Trademark Events
| Event Date | Event Description |
| Tuesday, April 2, 2024 | NEW APPLICATION ENTERED |
| Friday, September 6, 2024 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Friday, September 6, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, October 15, 2024 | NON-FINAL ACTION E-MAILED |
| Tuesday, October 15, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, October 15, 2024 | ASSIGNED TO EXAMINER |
| Tuesday, October 15, 2024 | NON-FINAL ACTION WRITTEN |
